Immunocytokines

Antibodies

Volumn 1, Issue 1, 2012, Pages 70-87

  Gutbrodt, Katrin L ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Antibodies; Antibody formats; Cancer; Chronic inflammatory disease; Cytokines; Immunocytokines; Immunotherapy

Indexed keywords

EID: 84873413455     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib1010070     Document Type: Review

References (94)

1. Miller, P.W.; Sharma, S.; Stolina, M.; Butterfield, L.H.; Luo, J.; Lin, Y.; Dohadwala, M.; Batra, R.K.; Wu, L.; et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum. Gene Ther. 2000, 11, 53–65.
2. Aoki, T.; Tashiro, K.; Miyatake, S.; Kinashi, T.; Nakano, T.; Oda, Y.; Kikuchi, H.; Honjo, T. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 1992, 89, 3850–3854.
3. Koshita, Y.; Lu, Y.; Fujii, S.; Neda, H.; Matsuyama, T.; Satoh, Y.; Itoh, Y.; Takahashi, M.; Kato, J.; Sakamaki, S.; et al. Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor. Int. J. Cancer 1995, 63, 130–135.
4. Barker, S.E.; Grosse, S.M.; Siapati, E.K.; Kritz, A.; Kinnon, C.; Thrasher, A.J.; Hart, S.L. Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br. J. Cancer 2007, 97, 210–217.
5. Jackaman, C.; Bundell, C.S.; Kinnear, B.F.; Smith, A.M.; Filion, P.; van Hagen, D.; Robinson, B.W.; Nelson, D.J. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J. Immunol. 2003, 171, 5051–5063.
6. Pasche, N.; Neri, D. Immunocytokines: A novel class of potent armed antibodies. Drug Discov. Today 2012.
7. Schrama, D.; Reisfeld, R.A.; Becker, J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5, 147–159.
8. Holliger, P.; Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23, 1126–1136.
9. Kuo, T.T.; Aveson, V.G. Neonatal Fc receptor and IgG-based therapeutics. MAbs 2011, 3, 422–430.
10. Woof, J.M.; Burton, D.R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 2004, 4, 89–99.
11. Ward, E.S.; Martinez, C.; Vaccaro, C.; Zhou, J.; Tang, Q.; Ober, R.J. From sorting endosomes to exocytosis: Association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol. Biol. Cell 2005, 16, 2028–2038.
12. Vaccaro, C.; Zhou, J.; Ober, R.J.; Ward, E.S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 2005, 23, 1283–1288.
13. Pop, L.M.; Liu, X.; Ghetie, V.; Vitetta, E.S. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life. Int. Immunopharmacol. 2005, 5, 1279–1290.
14. Jain, R.K.; Baxter, L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res. 1988, 48, 7022–7032.
15. Yokota, T.; Milenic, D.E.; Whitlow, M.; Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992, 52, 3402–3408.
16. Graff, C.P.; Wittrup, K.D. Theoretical analysis of antibody targeting of tumor spheroids: Importance of dosage for penetration, and affinity for retention. Cancer Res. 2003, 63, 1288–1296.
17. Milenic, D.E.; Yokota, T.; Filpula, D.R.; Finkelman, M.A.; Dodd, S.W.; Wood, J.F.; Whitlow, M.; Snoy, P.; Schlom, J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991, 51, 6363–6371.
18. Borsi, L.; Balza, E.; Bestagno, M.; Castellani, P.; Carnemolla, B.; Biro, A.; Leprini, A.; Sepulveda, J.; Burrone, O.; Neri, D.; Zardi, L. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 2002, 102, 75–85.
19. Holliger, P.; Prospero, T.; Winter, G. "Diabodies": Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993, 90, 6444–6448.
20. Kendra, K.; Gan, J.; Ricci, M.; Surfus, J.; Shaker, A.; Super, M.; Frost, J.D.; Rakhmilevich, A.; Hank, J.A.; Gillies, S.D.; Sondel, P.M. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol. Immunother. 1999, 48, 219–229.
21. Yamane, B.H.; Hank, J.A.; Albertini, M.R.; Sondel, P.M. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin. Investig. Drugs 2009, 18, 991–1000.
22. Johannsen, M.; Spitaleri, G.; Curigliano, G.; Roigas, J.; Weikert, S.; Kempkensteffen, C.; Roemer, A.; Kloeters, C.; Rogalla, P.; Pecher, G.; et al. The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur. J. Cancer 2010, 46, 2926–2935.
23. Ebbinghaus, C.; Ronca, R.; Kaspar, M.; Grabulovski, D.; Berndt, A.; Kosmehl, H.; Zardi, L.; Neri, D. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 2005, 116, 304–313.
24. Naramura, M.; Gillies, S.D.; Mendelsohn, J.; Reisfeld, R.A.; Mueller, B.M. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol. Lett. 1993, 39, 91–99.
25. Alderson, K.L.; Sondel, P.M. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J. Biomed. Biotechnol. 2011, 2011, 379123.
26. Buhtoiarov, I.N.; Neal, Z.C.; Gan, J.; Buhtoiarova, T.N.; Patankar, M.S.; Gubbels, J.A.; Hank, J.A.; Yamane, B.; Rakhmilevich, A.L.; Reisfeld, R.A.; et al. Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: Impact on conjugation, cytotoxicity, and targeting. J. Leukoc. Biol. 2011, 89, 625–638.
27. Gubbels, J.A.; Gadbaw, B.; Buhtoiarov, I.N.; Horibata, S.; Kapur, A.K.; Patel, D.; Hank, J.A.; Gillies, S.D.; Sondel, P.M.; Patankar, M.S.; Connor, J. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol. Immunother. 2011, 60, 1789–1800.
28. Patriarca, C.; Macchi, R.M.; Marschner, A.K.; Mellstedt, H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat. Rev. 2012, 38, 68–75.
29. Gires, O. Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol. Life Sci. 2011, 68, 4009–4022.
30. Mujoo, K.; Cheresh, D.A.; Yang, H.M.; Reisfeld, R.A. Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987, 47, 1098–1104.
31. Chang, H.R.; Cordon-Cardo, C.; Houghton, A.N.; Cheung, N.K.; Brennan, M.F. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 1992, 70, 633–638.
32. Svennerholm, L.; Bostrom, K.; Fredman, P.; Jungbjer, B.; Lekman, A.; Mansson, J.E.; Rynmark, B.M. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1994, 1214, 115–123.
33. Allen, M.; Louise Jones, J. Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J. Pathol. 2011, 223, 162–176.
34. Filer, A.; Pitzalis, C.; Buckley, C.D. Targeting the stromal microenvironment in chronic inflammation. Curr. Opin. Pharmacol. 2006, 6, 393–400.
35. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9, 653–660.
36. Schliemann, C.; Neri, D. Antibody-based vascular tumor targeting. Recent Results Cancer Res. 2010, 180, 201–216.
37. Neri, D.; Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer 2005, 5, 436–446.
38. Neri, D.; Carnemolla, B.; Nissim, A.; Leprini, A.; Querze, G.; Balza, E.; Pini, A.; Tarli, L.; Halin, C.; Neri, P.; Zardi, L.; Winter, G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 1997, 15, 1271–1275.
39. Schwager, K.; Villa, A.; Rosli, C.; Neri, D.; Rosli-Khabas, M.; Moser, G. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol. 2011, 3, 25.
40. Santimaria, M.; Moscatelli, G.; Viale, G.L.; Giovannoni, L.; Neri, G.; Viti, F.; Leprini, A.; Borsi, L.; Castellani, P.; Zardi, L.; Neri, D.; Riva, P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 2003, 9, 571–579.
41. Tarli, L.; Balza, E.; Viti, F.; Borsi, L.; Castellani, P.; Berndorff, D.; Dinkelborg, L.; Neri, D.; Zardi, L. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999, 94, 192–198.
42. Sharifi, J.; Khawli, L.A.; Hu, P.; King, S.; Epstein, A.L. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid. Hybridomics 2001, 20, 305–312.
43. Chen, S.; Yu, L.; Jiang, C.; Zhao, Y.; Sun, D.; Li, S.; Liao, G.; Chen, Y.; Fu, Q.; Tao, Q.; et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. 2005, 23, 1538–1547.
44. St Croix, B.; Rago, C.; Velculescu, V.; Traverso, G.; Romans, K.E.; Montgomery, E.; Lal, A.; Riggins, G.J.; Lengauer, C.; Vogelstein, B.; Kinzler, K.W. Genes expressed in human tumor endothelium. Science 2000, 289, 1197–1202.
45. Oh, P.; Li, Y.; Yu, J.; Durr, E.; Krasinska, K.M.; Carver, L.A.; Testa, J.E.; Schnitzer, J.E. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004, 429, 629–635.
46. Strassberger, V.; Fugmann, T.; Neri, D.; Roesli, C. Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer. J. Proteomics 2010, 73, 1954–1973.
47. Rybak, J.N.; Ettorre, A.; Kaissling, B.; Giavazzi, R.; Neri, D.; Elia, G. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat. Methods 2005, 2, 291–298.
48. Borgia, B.; Roesli, C.; Fugmann, T.; Schliemann, C.; Cesca, M.; Neri, D.; Giavazzi, R. A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res. 2010, 70, 309–318.
49. Frey, K.; Fiechter, M.; Schwager, K.; Belloni, B.; Barysch, M.J.; Neri, D.; Dummer, R. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp. Dermatol. 2011, 20, 685–688.
50. Schliemann, C.; Roesli, C.; Kamada, H.; Borgia, B.; Fugmann, T.; Klapper, W.; Neri, D. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood 2010, 115, 736–744.
51. Seruga, B.; Zhang, H.; Bernstein, L.J.; Tannock, I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 2008, 8, 887–899.
52. Douglas, M.R.; Morrison, K.E.; Salmon, M.; Buckley, C.D. Why does inflammation persist: A dominant role for the stromal microenvironment? Expert Rev. Mol. Med. 2002, 4, 1–18.
53. Zamarron, B.F.; Chen, W. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 2011, 7, 651–658.
54. McDermott, D.F.; Regan, M.M.; Atkins, M.B. Interleukin-2 therapy of metastatic renal cell carcinoma: Update of phase III trials. Clin. Genitourin. Cancer 2006, 5, 114–119.
55. Philip, P.A. Interleukin-2 in the treatment of malignant melanoma. Expert Opin. Investig. Drugs 1998, 7, 361–371.
56. Carnemolla, B.; Borsi, L.; Balza, E.; Castellani, P.; Meazza, R.; Berndt, A.; Ferrini, S.; Kosmehl, H.; Neri, D.; Zardi, L. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99, 1659–1665.
57. Schliemann, C.; Palumbo, A.; Zuberbuhler, K.; Villa, A.; Kaspar, M.; Trachsel, E.; Klapper, W.; Menssen, H.D.; Neri, D. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009, 113, 2275–2283.
58. Marlind, J.; Kaspar, M.; Trachsel, E.; Sommavilla, R.; Hindle, S.; Bacci, C.; Giovannoni, L.; Neri, D. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin. Cancer Res. 2008, 14, 6515–6524.
59. King, D.M.; Albertini, M.R.; Schalch, H.; Hank, J.A.; Gan, J.; Surfus, J.; Mahvi, D.; Schiller, J.H.; Warner, T.; Kim, K.; et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 2004, 22, 4463–4473.
60. Ribas, A.; Kirkwood, J.M.; Atkins, M.B.; Whiteside, T.L.; Gooding, W.; Kovar, A.; Gillies, S.D.; Kashala, O.; Morse, M.A. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J. Transl. Med. 2009, 7, 68.
61. Osenga, K.L.; Hank, J.A.; Albertini, M.R.; Gan, J.; Sternberg, A.G.; Eickhoff, J.; Seeger, R.C.; Matthay, K.K.; Reynolds, C.P.; Twist, C.; et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group. Clin. Cancer Res. 2006, 12, 1750–1759.
62. Shusterman, S.; London, W.B.; Gillies, S.D.; Hank, J.A.; Voss, S.D.; Seeger, R.C.; Reynolds, C.P.; Kimball, J.; Albertini, M.R.; Wagner, B.; et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study. J. Clin. Oncol. 2010, 28, 4969–4975.
63. Ko, Y.J.; Bubley, G.J.; Weber, R.; Redfern, C.; Gold, D.P.; Finke, L.; Kovar, A.; Dahl, T.; Gillies, S.D. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): Results of a phase I trial in patients with prostate cancer. J. Immunother. 2004, 27, 232–239.
64. Gillies, S.D.; Lan, Y.; Hettmann, T.; Brunkhorst, B.; Sun, Y.; Mueller, S.O.; Lo, K.M. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin. Cancer Res. 2011, 17, 3673–3685.
65. Yang, J.C.; Sherry, R.M.; Steinberg, S.M.; Topalian, S.L.; Schwartzentruber, D.J.; Hwu, P.; Seipp, C.A.; Rogers-Freezer, L.; Morton, K.E.; White, D.E.; et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 2003, 21, 3127–3132.
66. Rosenberg, S.A.; Yang, J.C.; White, D.E.; Steinberg, S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann. Surg. 1998, 228, 307–319.
67. Atkins, M.B.; Robertson, M.J.; Gordon, M.; Lotze, M.T.; DeCoste, M.; DuBois, J.S.; Ritz, J.; Sandler, A.B.; Edington, H.D.; Garzone, P.D.; et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 1997, 3, 409–417.
68. Halin, C.; Rondini, S.; Nilsson, F.; Berndt, A.; Kosmehl, H.; Zardi, L.; Neri, D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 2002, 20, 264–269.
69. Li, J.; Hu, P.; Khawli, L.A.; Yun, A.; Epstein, A.L. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid. Hybridomics 2004, 23, 1–10.
70. Rudman, S.M.; Jameson, M.B.; McKeage, M.J.; Savage, P.; Jodrell, D.I.; Harries, M.; Acton, G.; Erlandsson, F.; Spicer, J.F. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin. Cancer Res. 2011, 17, 1998–2005.
71. Lejeune, F.J.; Lienard, D.; Matter, M.; Ruegg, C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006, 6, 6.
72. Borsi, L.; Balza, E.; Carnemolla, B.; Sassi, F.; Castellani, P.; Berndt, A.; Kosmehl, H.; Biro, A.; Siri, A.; Orecchia, P.; et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102, 4384–4392.
73. Balza, E.; Mortara, L.; Sassi, F.; Monteghirfo, S.; Carnemolla, B.; Castellani, P.; Neri, D.; Accolla, R.S.; Zardi, L.; Borsi, L. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin. Cancer Res. 2006, 12, 2575–2582.
74. Huhn, R.D.; Radwanski, E.; O'Connell, S.M.; Sturgill, M.G.; Clarke, L.; Cody, R.P.; Affrime, M.B.; Cutler, D.L. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996, 87, 699–705.
75. Rosenblum, I.Y.; Johnson, R.C.; Schmahai, T.J. Preclinical safety evaluation of recombinant human interleukin-10. Regul. Toxicol. Pharmacol. 2002, 35, 56–71.
76. Schwager, K.; Kaspar, M.; Bootz, F.; Marcolongo, R.; Paresce, E.; Neri, D.; Trachsel, E. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res. Ther. 2009, 11, R142.
77. Schwager, K.; Bootz, F.; Imesch, P.; Kaspar, M.; Trachsel, E.; Neri, D. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Hum. Reprod. 2011, 26, 2344–2352.
78. Trachsel, E.; Kaspar, M.; Bootz, F.; Detmar, M.; Neri, D. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J. Invest. Dermatol. 2007, 127, 881–886.
79. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8, 59–73.
80. Moschetta, M.; Pretto, F.; Berndt, A.; Galler, K.; Richter, P.; Bassi, A.; Oliva, P.; Micotti, E.; Valbusa, G.; Schwager, K.; et al. Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts. Cancer Res. 2012, 72, 1814–1824.
81. Holden, S.A.; Lan, Y.; Pardo, A.M.; Wesolowski, J.S.; Gillies, S.D. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin. Cancer Res. 2001, 7, 2862–2869.
82. Pedretti, M.; Verpelli, C.; Marlind, J.; Bertani, G.; Sala, C.; Neri, D.; Bello, L. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br. J. Cancer 2010, 103, 827–836.
83. Johnson, E.E.; Yamane, B.H.; Buhtoiarov, I.N.; Lum, H.D.; Rakhmilevich, A.L.; Mahvi, D.M.; Gillies, S.D.; Sondel, P.M. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin. Cancer Res. 2009, 15, 4875–4884.
84. Hornick, J.L.; Khawli, L.A.; Hu, P.; Sharifi, J.; Khanna, C.; Epstein, A.L. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin. Cancer Res. 1999, 5, 51–60.
85. Liu, Z.; Smyth, F.E.; Renner, C.; Lee, F.T.; Oosterwijk, E.; Scott, A.M. Anti-renal cell carcinoma chimeric antibody G250: Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 2002, 51, 171–177.
86. Friedberg, J.W.; Neuberg, D.; Gribben, J.G.; Fisher, D.C.; Canning, C.; Koval, M.; Poor, C.M.; Green, L.M.; Daley, J.; Soiffer, R.; et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol. 2002, 117, 828–834.
87. Frey, K.; Schliemann, C.; Schwager, K.; Giavazzi, R.; Johannsen, M.; Neri, D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J. Urol. 2010, 184, 2540–2548.
88. Halin, C.; Gafner, V.; Villani, M.E.; Borsi, L.; Berndt, A.; Kosmehl, H.; Zardi, L.; Neri, D. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 2003, 63, 3202–3210.
89. Gillies, S.D.; Lan, Y.; Brunkhorst, B.; Wong, W.K.; Li, Y.; Lo, K.M. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol. Immunother. 2002, 51, 449–460.
90. Connor, J.P.; Stupp, R.; Cristea, M.C.; Lewis, N.; Lewis, L.D.; Mattiacci, M.R.; Felder, M.; Stewart, S.; Henslee-Downey, J.; Neugebauer, R.; Komarnitsky, P.B. Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. J Clin Oncol 2011, 29, 2011 (suppl; abstr 2556).
91. De Braud, F.G.; Catania, C.; Onofri, A.; Pierantoni, C.; Cascinu, S.; Maur, M.; Masini, C.; Conte, P.F.; Giovannoni, L.; Tasciotti, A.; Lovato, V.; Neri, D.; Menssen, H.D. Combinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors. J Clin Oncol 2010, 28, 2010 (suppl; abstr e13017).
92. Eigentler, T.K.; Weide, B.; de Braud, F.; Spitaleri, G.; Romanini, A.; Pflugfelder, A.; Gonzalez-Iglesias, R.; Tasciotti, A.; Giovannoni, L.; Schwager, K.; et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin. Cancer Res. 2011, 17, 7732–7742.
93. Tijink, B.M.; Perk, L.R.; Budde, M.; Stigter-van Walsum, M.; Visser, G.W.; Kloet, R.W.; Dinkelborg, L.M.; Leemans, C.R.; Neri, D.; van Dongen, G.A. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1235–1244.
94. Bassani-Sternberg, M.; Barnea, E.; Beer, I.; Avivi, I.; Katz, T.; Admon, A. Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc. Natl. Acad. Sci. USA 2010, 107, 18769–18776.